Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy: a retrospective review of medical records
Abstract Background Hepatitis C virus (HCV) is common among individuals in opioid agonist therapy (OAT). HCV treatment has previously been unavailable for most HCV positive OAT patients in Finland. The removal of treatment restrictions and attempts to reach HCV elimination goals have increased the n...
Saved in:
Main Authors: | Margareeta Häkkinen (Author), Jouni Tourunen (Author), Tuuli Pitkänen (Author), Kaarlo Simojoki (Author), Sauli Vuoti (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
by: Vorma Helena, et al.
Published: (2008) -
Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
by: Kirsten Marchand, et al.
Published: (2020) -
Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review
by: Em M. Pijl, et al.
Published: (2022) -
Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
by: Anne Berit Bech, et al.
Published: (2019) -
A qualitative study of experiences with physical activity among people receiving opioid agonist therapy
by: Einar Furulund, et al.
Published: (2024)